본문 바로가기
KERD
논문KCI 등재

Mental Disorders and Interferon Nontreatment in Hepatitis C Virus Infection-a Population Based Cohort Study

Cheng-Chen Chang|Wei-Che Chiu|Mong-Liang Lu
대한신경정신의학회 (Korean Neuropsychiatric Association)|2020.03|PSYCHIATRY INVESTIGATION|제17권 제3호|pp. 268-274|DOI https://doi.org/10.30773/pi.2019.0254

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

AnxietyMental disordersDepression.Hepatitis CInterferon non-treatment
주제분류정신과학

초록

Objective This study investigates the association between mental disorders and interferon nontreatment in patients with chronic hepatitis C virus (HCV) infection in a large national sample. Methods Using the National Health Insurance Research Database of Taiwan, we conducted a nationwide population-based study. Each case was matched to five controls by age, sex, urbanization, and income. Conditional logistic regression was used to assess odds of HCV nontreatment in different mental disorders. Results From 1999 to 2013, we identified 92,970 subjects with HCV infection and 15,495 HCV cases (16.7%) had received IFN therapy. Other than chronic obstructive pulmonary disease, the medical diseases and mental disorders were significantly different between IFN and non-IFN treated HCV patients. After adjusting for medical diseases, depressive disorder and anxiety disorder was positively associated with receiving IFN therapy. Patients with schizophrenia, bipolar disorders and alcohol use disorders were significantly less likely to receive interferon. Antidepressant exposure (cumulative daily exposure or cumulative daily dose) was associated with lower odds of IFN treatment. Conclusion Our nationwide cohort study demonstrated that INF nontreatment rate was lower in certain mental disorders. Antidepressant exposure might lower the chance of receiving IFN treatment. Our results may help to identify and to overcome the obstacles for HCV treatment and further apply to DAAs regimen.

Abstract

Objective This study investigates the association between mental disorders and interferon nontreatment in patients with chronic hepatitis C virus (HCV) infection in a large national sample. Methods Using the National Health Insurance Research Database of Taiwan, we conducted a nationwide population-based study. Each case was matched to five controls by age, sex, urbanization, and income. Conditional logistic regression was used to assess odds of HCV nontreatment in different mental disorders. Results From 1999 to 2013, we identified 92,970 subjects with HCV infection and 15,495 HCV cases (16.7%) had received IFN therapy. Other than chronic obstructive pulmonary disease, the medical diseases and mental disorders were significantly different between IFN and non-IFN treated HCV patients. After adjusting for medical diseases, depressive disorder and anxiety disorder was positively associated with receiving IFN therapy. Patients with schizophrenia, bipolar disorders and alcohol use disorders were significantly less likely to receive interferon. Antidepressant exposure (cumulative daily exposure or cumulative daily dose) was associated with lower odds of IFN treatment. Conclusion Our nationwide cohort study demonstrated that INF nontreatment rate was lower in certain mental disorders. Antidepressant exposure might lower the chance of receiving IFN treatment. Our results may help to identify and to overcome the obstacles for HCV treatment and further apply to DAAs regimen.

참고문헌 (37)

  1. Poynard T, "Viral hepatitis C", Lancet, 362, pp.2095~2100 (2003)
  2. Shiffman ML, "Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial", Gastroenterology, 137, pp.1986~1994 (2009)
  3. NIH Consensus Statement on Management of Hepatitis C, "NIH Consens State Sci Statements", 19, pp.1~46 (2002)
  4. Okanoue T, "Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy", Clin Gastroenterol Hepatol, 3, pp.S89~S91 (2005)
  5. Chu CJ, "Hepatitis B virus", hepatitis C virus coinfection : epidemiology, clinical features, viral interactions and treatment, 2008, pp.23, 512~520
  6. Chen DS, "Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease : the Taiwan experience", J Infect Dis, 162, pp.817~822 (1990)
  7. Lee SD, "Seroepidemiology of hepatitis C virus infection in Taiwan", Hepatology, 13, pp.830~833 (1991)
  8. Chuang WL, "The role of hepatitis C virus in chronic hepatitis B virus infection", Gastroenterol Jpn, 28(Suppl 5), pp.23~27 (1993)
  9. Lu SN, "Different viral aetiology of hepatocellular carcinoma between two hepatitis B and C endemic townships in Taiwan", J Gastroenterol Hepatol, 12, pp.547~550 (1997)
  10. Wang JH, "A hyperendemic community of hepatitis B virus and hepatitis C virus infection in Taiwan", Trans R Soc Trop Med Hyg, 93, pp.253~254 (1999)
  11. Adinolfi LE, "Chronic hepatitis C virus infection and neurological and psychiatric disorders : an overview", World J Gastroenterol, 21, pp.2269~2280 (2015)
  12. Hadziyannis SJ, "Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C : a randomized study of treatment duration and ribavirin dose", Ann Intern Med, 140, pp.346~355 (2004)
  13. Falck-Ytter Y, "Surprisingly small effect of antiviral treatment in patients with hepatitis C", Ann Intern Med, 136, pp.288~292 (2002)
  14. Restrepo A, "The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre", J Viral Hepat, 12, pp.86~90 (2005)
  15. Fleming CA, "Hepatitis C virus and human immunodeficiency virus coinfection in an urban population : low eligibility for interferon treatment", Clin Infect Dis, 36, pp.97~100 (2003)
  16. Evon DM, "Adherence to PEG", ribavirin treatment for chronic hepatitis C : prevalence, patterns, and predictors of missed doses and nonpersistence, 2013, pp.20, 536~549
  17. Evon DM, "Barriers to accessing care in patients with chronic hepatitis C : the impact of depression", Aliment Pharmacol Ther, 32, pp.1163~1173 (2010)
  18. Butt AA, "Rate and predictors of treatment prescription for hepatitis C", Gut, 56, pp.385~389 (2007)
  19. Schaefer M, "Hepatitis C infection, antiviral treatment and mental health : a European expert consensus statement", J Hepatol, 57, pp.1379~1390 (2012)
  20. Dieperink E, "Neuropsychiatric symptoms associated with hepatitis C and interferon alpha : a review", Am J Psychiatry, 157, pp.867~876 (2000)
  21. Yan KK, "Rate and factors affecting treatment uptake of patients with chronic hepatitis C in a tertiary referral hospital", Dig Dis Sci, 55, pp.3541~3547 (2010)
  22. Mendes-Correa MC, "Barriers to treatment of hepatitis C in HIV", HCV coinfected adults in Brazil, 2010, pp.14, 237~241
  23. Chou PH, "Prevalence of allergic rhinitis in patients with attention-deficit", hyperactivity disorder : a population-based study, 2013, pp.22, 301~307
  24. Tsan YT, "Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection", J Clin Oncol, 31, pp.1514~1521 (2013)
  25. Yang YH, "Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection", J Hepatol, 63, pp.1111~1117 (2015)
  26. Wacholder S, "Selection of controls in case-control studies. III. Design options", Am J Epidemiol, 135, pp.1042~1050 (1992)
  27. "World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC classification index with DDDs"[URL]
  28. Sockalingam S, "Psychiatric care during hepatitis C treatment : the changing role of psychiatrists in the era of direct-acting antivirals", Am J Psychiatry, 172, pp.512~516 (2015)
  29. Yehia BR, "The treatment cascade for chronic hepatitis C virus infection in the United States : a systematic review and meta-analysis", PLoS One, 9, pp.e101554~ (2014)
  30. Kramer JR, "Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans : a national study", Am J Gastroenterol, 106, pp.483~491 (2011)
  31. Chainuvati S, "Comparison of hepatitis C treatment patterns in patients with and without psychiatric and", or substance use disorders, 2006, pp.13, 235~241
  32. Schaefer M, "Management of mental health problems prior to and during treatment of hepatitis C virus infection in patients with drug addiction", Clin Infect Dis, 57(Suppl 2), pp.S111~S117 (2013)
  33. Grebely J, "Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV", HIV coinfection: action required at the system, provider, and patient levels, 2013, pp.207(Suppl 1), S19~S25
  34. Kanwal F, "Predictors of treatment in patients with chronic hepatitis C infection-role of patient versus nonpatient factors", Hepatology, 46, pp.1741~1749 (2007)
  35. Nelligan JA, "Depression comorbidity and antidepressant use in veterans with chronic hepatitis C : results from a retrospective chart review", J Clin Psychiatry, 69, pp.810~816 (2008)
  36. Kravitz RL, "Introduction : chronic medical conditions and depression--the view from primary care", Am J Med, 121, pp.S1~S7 (2008)
  37. Barney LJ, "Stigma about depression and its impact on help-seeking intentions", Aust N Z J Psychiatry, 40, pp.51~54 (2006)

관련 논문AI추천

Prevalence and Incidence of Depression during Interferon-Based Antiviral Therapy in Chronic Hepatitis C Patients in the Republic of Korea김영석, 김인희, 김진욱, 백주영, 서승영, 장은선, 정숙향, 정은욱, 조준현, 천정화거트앤리버 소화기연관학회협의회 · Gut and Liver2017 · 제11권 제3호Association of Changes in Mood Status and Psychosocial Well-Being with Depression During Interferon-Based Treatment for Hepatitis C김원, 김휘영, 손보경, 오소희, 이준영, 정용진, 정희연, 주세경, 최정석대한신경정신의학회 · PSYCHIATRY INVESTIGATION2017 · 제14권 제3호Completion of Chronic Hepatitis C Virus Treatment in Interferon-Induced Major Depressive Disorder with Psychotic FeaturesSusie H. Park대한신경정신의학회 · PSYCHIATRY INVESTIGATION2011 · 제8권 제4호Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study정정화, Choi Hwa Young, Jang Eun Sun, Jeong Sook-Hyang, Ki Moran거트앤리버 소화기연관학회협의회 · Gut and Liver2021 · 제15권 제2호Association between new-onset liver cirrhosis and suicide risk in South Korea: A nationwide cohort study은혁수, Byung Seok Lee, Seok Hyun Kim, Suk-Yong Jang, Woo Sun Rou대한간학회 · Clinical and Molecular Hepatology2021 · 제27권 제2호페그인터페론 치료를 받는 만성바이러스성 간염 환자의 불안에 관한 연구김수인, 김지현, 김태헌, 최희연대한신경정신의학회 · 신경정신의학2015 · 제54권 제4호

이 간행물의 다른 논문 (11건)

Major Depressive Disorder: Current Advances and Paradigm ShiftsYong-Ku Kimpp. 179-180Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives김용구, 신민철pp. 181-192Personalized Psychiatry and Depression: The Role of Sociodemographic and Clinical VariablesGiampaolo Perna, Alessandra Alciati, Silvia Daccò, Massimiliano Grassi, Daniela Caldirolapp. 193-206Understanding the Complex of Suicide in Depression: from Research to ClinicsAlessandro Valchera, Maurizio Pompili, Giovanni Martinotti, Silvia Fraticelli, Roberto Latini, Carmine Tomasetti, Raffaella La Rovere, Domenico De Berardis, Gianluca Serafini, Laura Orsolini, Umberto Volpe, Michele Fornaro, Sabatino Trotta, Federica Vellante, Marco Alessandrini, Massimo Di Giannantoniopp. 207-221The Hypothesis on the Prediction of Treatment Response with Buspirone Augmentation along with Serotonergic Antidepressant in Patients with Major Depressive Disorder Using Loudness Dependence of Auditory Evoked Potentials: Two Cases and Review of the Literature for EvidenceYoung-Min Parkpp. 222-224
원문 보기